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I.INTRODUCTION AND SUMMARY
The United States faces a health care crisis in the years ahead.
Spiraling costs are quickly outpacing the rate of ination. Many people do not
feel the immediate pressure as the true cost of America's health care is borne by
employer or government provided insurance. One can rest assured the consumer
is the ultimate payer however.
One signicant part of health care cost which is frequently borne
directly by consumers is medication. Most insurance does not fully cover this
part of health. Many people on xed income and below the poverty line are
seeing their savings devoured by the pharmaceutical industry.
The partial solution to this problem is to switch more drugs from
prescription to over the counter status. Over the counter drugs do not require
an expensive and annoying visit to the doctor and are consistently cheaper. Also
gratifying with OTC switches is that OTC drugs do not require the same direct
marketing, a.k.a. gifts, to physicians. In other words, the consumer does not
have to pay for that winter conference in Barbados sponsored by Eli Lilly.
Obstacles to more OTC switching include a risk-averse FDA and a
hypersensitive and territorial health care industry. The manifestation of these
obstacles can be seen with the defeated switch attempts of rogaine, H2-blockers,
1and oral contraceptives.
In order to overcome these obstacles, the FDA should create a third
class of drugs to be dispensed only at the discretion of the pharmacist. This
would allow for patient counseling and alleviate the safety concerns of the FDA
and health care industry.
II.THE BITTER PILL PROBLEM a.The Problem Detailed.
On Monday, September 28, 1992, a hearing was held before the
Select Committee on Aging and the Subcommittee on Housing and Consumer
Interests to discuss a problem facing the aged and other consumers in this
country. With a few horrifying statistics, the problem was clearly set before
everyone present. In 1991, our nation spent almost $700 billion on health care,
over $32 billion for prescription drugs outside of hospitals. In the previous
decade, prescription drug prices went up about three times the rate of ination.
What was a $20 prescription in 1980 cost $53.76 in 1991 and is projected to
cost $120 in the year 2000 if something is not done.1
The pharmaceutical industry has often responded to accusations of
price gouging by explaining that a great deal of money is needed to develop the
wonder drugs of tomorrow and that patents run out quickly in the drug indus-
try. Unfortunately, this simply does not hold up under scrutiny. The hearing
mentioned above also presented the statistic that the average pharmaceutical
company has a prot of 15.5%, which triples the prot of the average Fortune
500 company. This 15.5% prot is determined after research and development
1Prescription Drug Costs: A Bitter Pill to Swallow, Hearing Before the U.S. House of
Representatives, Select Committee on Aging, Joint with its Subcommittee on Housing and
Consumer Interests, 102nd Congress, 2nd Sess., September 28, 1992.
2is taken out as an expense 2
Another statistic the pharmaceutical industry is reluctant to reveal
is how much money is spent on marketing the drugs which are so costly to
develop. According to data released by the Senate Labor and Human Resources
Committee, drug company expenditures on marketing account for about 15% of
their revenues, ~ than they spend on research and development. This translates
to $5 billion, or more than $8,000 per M.D. and D.O. per year.3
What is also interesting about the above gure is that while the
consumer ultimately bears the cost of the marketing expense, the doctor receives
the benet. Prescription drug marketing is aimed directly to the health care
provider. Relating her personal experience with the pharmaceutical industry,
Mary-Margaret Chren, Senior Clinical Instructor, Department of Dermatology,
University Hospitals Cleveland, relates that some of the marketing techniques
include outright gifts. These gifts included: a check for $156 made out to her
as a senior resident; an invitation to stay - all expenses paid -for six nights at
Loew's L'Enf ant Plaza, a Washington Hotel; and textbooks valued at $495.4
Making the situation even more unjust is the fact that many of
the consumers cannot aord to pick up the tab for the high prot margins and
thinly veiled bribery of medical ocials. The spiraling costs of health care are
always eventually borne by consumers. However,, in the case of prescription
drugs the cost hits very directly ~xid deeply into thA pockets of the consumer..
2ibid.
3Mary-Margaret Chren, The Need for Guidelines About Pharmaceutical Promotions In-
volving Gifts to Physicians, Promotion of Pharmaceuticals: Issues. Trends. ODtions, (Phar-
maceutical Products Press, 1992) 136.
4Id.
3For instsnce, the average prescription drug costs $24 plus $45 for the doctor's
appointment to obtain the drug. While some type of health insurance will pick
up the doctor's tab, the consumer will pay the prescription costs 75% of the
time.5
This cost is simply impossible for some to aord. Many people on
xed incomes cannot keep up with prices which triple the rate of ination.
Illustrating how real the problem has become is the situation in
rural New Mexico. Primarily a rural state, many citizens of that state cannot
reach a doctor even if they could aord the medicines he would provide. Rather
than going without food so that they can buy medicine, the people are more
and more frequently crossing over into Mexico to purchase drugs. In Mexico,
even prescription drugs can be obtained by simply telling the pharmacists what
is wrong and asking for medication. A study in 1990 found that over 87% of
the patients at a rural health clinic in New Mexico had obtained medication in
Mexico. Low cost and easy accessibility were the primary reason for purchasing
the drug.6
The great concern with this activity is that the Mexican pharmacist
has limited training and resources. Serious illness maybe misdiagnosed. Side
eects and adverse drug interaction are much more likely. Furthermore, the
individual's doctor cannot track the drug record of the patient.
The inaccessibility of prescription drugs is prevalent throughout the
U.S. Of course, many patients do not have the option of travellir~g somewhere to
5Prescription Drug Costs: A Bitter Pill to Swallow.
6Stephen R. Tabes, and William H. Wiese, Medications Obtained in Mexico by Patients
in Southern New Mexico, Southern Medical Journal, vol. 83, no. 3, March 1990, 271.
4obtain cheaper drugs. Frequently the options are to simply go without medicine
or go without food. Either choice will cost everyone more than if the drugs had
been accessible in the rst place. b.A Step in the Riciht Direction - OTC Switches
One partial solution could be switching more drugs o prescription
status. The hearing on September 28, 1992 before the Select committee Hearing
on Aging considered several options to deal with the problem of escalating pre-
scription costs. Ideas such as price caps and other forms of direct government
intervention were mentioned. The problem is massive enough to require more
than one simple answer. However, this paper will argue the committee failed
to consider a very important option which actually calls for the government to
pull back somewhat and let market forces help solve the problem. The FDA
should consider switching more drugs over to OTC status.
OTC drugs already have proven invaluable in holding down health
care costs and allowing consumers to quickly and eciently treat their health
problems. According to William Soller, senior vice president and director of sci-
ence and technology, Nonprescription Drug Manufacturers Association, Ameri-
cans self-treat with OTC drugs 60% of the time. That self-treatment, however,
only represents 2% of health care costs.7
Before one dismisses the potential for OTC drug expansion, con-
sider the eect when patients decide not to try selftreatment. Soller contends
that if consumers switched from self-treatment to medical help only 2% more of
the time, the annual increase in patients' oce visits would be a staggering 300
7William Soller, Outlook for OTC Switches, American Pharmacy, Vol. NS31, No. 2,
February 1991, 106.
5million per year - more than a 60% increase. To understand the cost of that
increase consider Chicago during the 1982 product tampering scare. During
the three month scare, patients switched from OTC to prescription 27% more
frequently resulting in an added $382 million to the cost of health care.8
The potential in savings after OTC switches can be seen in specic
examples as well. Hydrocortisone, (.5%), was switched in 1979. From 1979 to
1981, health care costs were reduced by $600 million as a result of the switch.
Professor Peter Temin at the Massachusetts Institute of Technology calculated
that 12 switches of cough/cold medication save the American people $750 million
each year.
With this great potential for savings at the government's disposal,
the question becomes why does the government not switch more drugs over to
OTC? Not every prescription drug is ideal for switching, but there are many
qualied candidates. More drugs are not switched because of the limited re-
sources and natural lethargy of the Food and Drug Administration (FDA).
Also limiting switches are health ocials' hypersensitivity to safety concerns
and self-interest prejudice.
III.THE OBSTACLES TO MORE EFFICIENT HEALTH CARE
a.The Problem of the Limited Resources and Letharcw of the FDA.
To understand how the FDA obstructs prescription to OTC switches,
a brief history of OTC would be helpful. The history reveals that when the FDA
focuses its limited resources on OTC drugs, much more progress and savings
8ibid.
6are realized. However, when the agency moves on, these opportunities are lost.
The Federal Food, Drug, and Cosmetic Act of 1938 does not contain a specic
denition of OTC drugs. By implication of the act however, OTC drugs are
drugs having characteristics that do not call for prescription dispensing. The
1951 Humphrey-Durham Amendment to the FDCA formalized the distinction.
The FDA's regulation claried the distinction by permitting a drug to be OTC,
unless, because of its toxicity or other potential for harmful eect or because
the method of collateral measures necessary to its use, it may safely be sold and
used only under the supervision of a practioner.9
For the most part, OTC drugs remained minor remedies for minor
problems. They were drugs intended to provide relief of symptoms while nature
took its own healing course. In 1972, the FDA began an intensive systematic
scrutiny of the OTC drug industry. The investigation focused on the safety,
ecacy, and labeling of all OTC drugs. The drugs were grouped into thera-
peutic classes and advisory panels were established to review each class. The
investigation was completed a full eleven years later in 1983, and the panels
were disbanded shortly thereafter.10
The lasting contribution of these panels was the establishment of
monographs for each category of drugs. Each monograph contains the active
ingredients which may be used in each type of OTC drug. Also included in the
monograph is the approved labelling and any required warnings. The system
thus requires that each new candidate for OTC must conform to the established
921 CFR 330.l0(a)(4)(vi).
10Commerce ClearinQ House. Food DruQ Cosmetic Law ReDorts, paragraph 72,001.
7monograph or submit a new drug application requiring extensive clinical testing
and review.11
While the far-reaching review by the advisory panels and estab-
lishment of the monograph system helped bring the OTC under control, it also
stied innovation and eciency. The Nonprescription Drug Manufacturers As-
sociation became disgruntled by the process. Having numerous candidat~n fnr
~'C Qi-~*us, the NDMA saw its products tied up for years in a bureaucracy of
limited resources and unlimited red tape. From 1951 to 1976, the period before
the monograph system, the FDA approved switches at a rate less than one per
year. From 1977-84, when the panels focused the FDA's attention to the po-
tential of switches, the FDA approved 2.8 per year. However, after the OTC
advisory panels disbanded in the mid-80's, the rate slipped again - back to 1.33
per year.12 The FDA had focused it~ M~i~~in~ and limited budget elsewhere.
The FDA's lack of focus has been somewhat alleviated by the cre-
ation of the Oce of OTC Drug Evaluation and the Nonprescription Drugs
Advisory Committee in 1991. According to a 1993 article in the Food & Drug
Law Journal, the Nonprescription Drug Advisory Committee was created to
review data on the safety and eectiveness of OTC drugs, and to advise the
Commissioner and the Oce of the OTC Drug Evaluation on monograph or
new drug applications.
The creation of the OTC Oce and its corresponding advisory
panel allows the OTC drug industry greater participation in the evaluation
11ibid.
12Soller, 107.
8process.13 This is a step in the right direction. While government ocials
might let an application languish for years, private rms will push the issue
much harder. The FDA will be forced to give higher priority to OTC switches.
Even with private participation there still remains the problem of
the FDA's natural lethargy. Ultimately, the FDA still has to make the decision
to approve a prescription to OTC switch. This calls for the FDA to take a risk
and open itself up to criticism and responsibility should the drug prove unsafe.
An FDA ocial can make a career of turning down OTC switch applications.
However, if an approved OTC switch ever turns out to be a mistake, that
ocial's career can be quickly cut short. Thus, if one is going to try to reach
the goal of switching more drugs to OTC, the risk of unsafe switches should be
minimized.
b.The HvDersensitivitv and Self-Interest of Health Ocials.
Compounding the problem of government ocials unwilling to take
a risk is the hypersensitivity of health ocials to safety concerns as well. Both
health ocials and government agencies have the same basic problem when it
comes to making a decision as to whether a drug is a good candidate for OTC.
They only experience the downside should their decisions prove wrong. Even
worse, health ocials face a downside even if the drug switched to OTC proved
to be a good choice. Health ocials will lose all the direct marketing gifts and
donations from the drug company which as mentioned above is very substantial.
Even more troubling would be the loss of income as patients eectively treat
13Eve E. Bachrach, The FDA's New Over-the-Counter Drug Oce and Advisory Commit-
tee: An Industry Perspective, 48 Food & DruQ Law Journal 563.
9their illnesses without ever passing through the physicians' waiting rooms.
Thus, one is not surprised that studies nd health ocials hyper-
sensitive to safety concerns when discussing OTC switches. A good example of
this hypersensitivity is a 1989 study of pharmacists' evaluation of four drugs. A
questionnaire was constructed for three potential switch candidates (metapro-
terenol, cimetidine, and nystatin) and one already switched drug (ibuprofen).
The survey revealed that pharmacists perceived all four drugs as being very
eective for their suggested nonprescription indication, but they were not com-
fortable with the safety of the drugs when used on a nonprescription.14
With the benet of hindsight one can see that safety concerns, at
least for ibuprofen, were exaggerated. Having been on the market for over
ten years, ibuprofen has proven a very eective pain reliever. Consumers have
shown they can use the drug safely. Whether obtaining oral advice from phar-
macists or simply reading the label, consumers are capable of understanding
their symptoms and carefully taking the right medication as directed.
The question then becomes whether the health ocials' fear of
many other drugs are just as poorly grounded. Unfortunately, the FDA is in no
position to challenge the medical establishment and health ocials when they
begin to warn of possible dangers. The public is never allowed to prove that it
is capable of treating itself in many cases.
IV.SPECIFIC EXAMPLES
14Suresh Madhavan and Stephen W. Schondelmeyer, Pharmacists' Evaluation of the
Nonprescription Availability of Metaproterenol, Cimetidine, Ibuprofen and Nystatin,
American Journal Of Hospital Pharmacy, vol. 46, Dec. 1989, 2492.
10In order to show the obstacles to OTC switches in action, three
candidates will be discussed: rogaine, histamine(sub2)-blocker therapy, and oral
contraceptives.
a. Rogaine.
Rogaine was approved for prescription use in 1987 to treat certain
forms of male pattern baldness. FDA's approval was based on ecacy data
showing that at four months, the active group had an average increase of 72
hairs while subjects in the placebo group had an average increase of 39 hairs.
27% of patients perceived an increase in hair growth, and physicians perceived
hair growth in 32% of patients.15
Upjohn, the maker of rogaine, desired to expand the market poten-
tial for the drug and submitted an application for switching the drug. Rather
than simply relying on the data from the original clinical trials needed for
prescription approval, Upjohn submitted a favorable one-year post-marketing
surveillance study of 11,222 patients perceptions and satisfaction with rogaine.
With only minor and relatively harmless side eects shown to occur from the
drug, Upjohn felt condent the drug would be approved.16
However, the risk averse nature of the FDA pulled through and
the drug was not approved for an OTC switch. The Nonprescription Drugs
Advisory Committee voted against the switch because it was feared patients
could not accurately diagnose whether the product was needed or not. Rogaine
15Rogaine RX-to-OTC Switch Stumbles on Issue of Baldness Misdiagnosis: Advisory Com-
mittee Splits Hairs About Meaningful Ecacy; Actual-Use Study Urged, FDC Report,
The Pink Sheet, August 1, 1994, 2.
16'ibid.
11only treats a certain form of baldness. Since rogaine requires long-term use
before any results could be seen, the committee feared consumers would be
frustrated and a great deal poorer. Importantly, however, the committee felt
there were no real safety concerns.17
Rogaine remains a prescription product today. Because committee
members feared people were incapable of diagnosing what type of baldness they
had and would be frustrated, balding consumers remain frustrated. They ei-
ther must take the trouble of arranging a doctor's appointment, paying for the
visit directly out of pocket or through health insurance, and then paying the
higher cost of the prescription rogaine (which includes the marketing cost to the
doctor).
The committee would be better of f trusting the consumer as they
did with ibuprofen. Patients can diagnose themselves surprisingly well. At the
very least, the patients will simply be out of money and frustrated. Many people
are in that state of frustration today as they cannot aord to take the time to
arrange a doctor's appointment. b.Histamine(sub2)-blockers (H2-blockers).
H2-blockers are prime candidates for an OTC switch. This type of
drugs is frequently used in the treatment of peptic ulcer disease. Duodenal ulcer
healing occurs in 75-80% of patients after four weeks of H2-blocker treatment.
The potential market for this type of drug is quite large. A recent survey found
that 25% of Americans had at least one episode of dyspepsia during an average
two-week period. The directions for use would be similar to antacids - for the
17ibid. 1.
12relief of heartburn, acid indigestion, sour stomach, hyperacidity, or dyspepsia.18
There are two main concerns when discussing the switch of H2-
blockers to OTC. The rst concern is that patients will cease using the drug
after the symptoms cease causing incomplete treatment of the disorder and
complications. The second concern is that H2 blockers have potential drug
interaction problems, particularly with cimetidine.19
Admittedly, these concerns are much more legitimate than the con-
cerns mentioned for rogaine above. However, the two concerns are not sucient
reasons to keep the drug prescription. Since many consumers are using antacids
to treat the same symptoms, the problem of untreated underlying disorders is
arguably greater with the present system. More importantly, the fear of im-
proper use and drug interaction can be alleviated if the drug is sold only at
the discretion of the pharmacists - much as penicillin is today. Of course, this
would require more innovation and expense from the FDA. Once again, the
consumer's needs are thwarted by bureaucracy as H2-blockers remain available
in prescription only. c.Oral Contraceptives.
Talk of providing oral contraceptives OTC has been present ever
since this option of birth control was introduced. However, with each pass-
ing year the arguments for such a switch grow and the drawbacks seem less
important. The biggest argument for such a switch is the chronic problem
this country faces with unwanted pregnancies. According to a recent article in
18Edgar r. Gonzalez and Joseph A. Grillo, Over the Counter Histamine(sub 2) - Blocker
Therapy, Annals of PharmacotheraDy, vol. 28, March 1994, 393.
19ibid.
13American Health, there are over 3.5 million unintended pregnancies each year
and1.6million abortions.20 Frequently, these children are born into families that
simply cannot aord to raise them. While social programs can sometimes al-
leviate some of the pressure, today's political climate suggest that decreasing
unwanted pregnancies is a goal upon which most people can agree.
The biggest problem often raised with switching oral contraceptives
to OTC is safety. The drugs are known to have serious side eects, particularly
with long term use. Dosage and type frequently need adjusting for the optimum
eect. The most immediate response to this concern is that while safety should
remain a concern, the present system puts more women at risk than any system
of OTC oral contraceptives. Pregnancy, especially among the poor where health
care access is limited, is much more dangerous than oral contraceptives. Too,
other forms of birth control such as abortion are obviously more traumatic and
dangerous than taking the pill.
At the bottom of the whole matter is whether women can under-
stand the proper use, limits, and side eects of oral contraceptives. Like other
drugs which have been switched, consumers need information and time to ma-
ture in understanding of the drug. Once oral contraceptives are switched, that
process could begin. The process would not be dicult. The two most im-
portant factors to determine dosage are age and smoking status. Mistakes in
dosage or type can be troubling - but not extremely serious. Pill overdoes leads
to vomiting but has never proven fatal - a fact which cannot be said for other
20Winif red Conkling, Contraceptive Compromise: Switching the Pill to OTC,
American Health, vol. 13, March 1994.
14OTC medication.21
As with the H2-blockers, oral contraceptives might be good can-
didates for sale at the discretion of the pharmacist. As Nancy Buc, former
senior counsel to the FDA, commented at a Kaiser Family Foundation meeting
in California, In the end, who's in charge-the woman or the doctor?22
V.SOLUTIONS
a.Create a third class of druQs.
The basic dilemma presented in sections II - IV above is that pre-
scription drugs are simply too expensive for many consumers. A switch to OTC
can often reduce the costs of medication and make them more accessible to those
in need of treatment. However, the FDA and the health care industry are often
too lethargic and hypersensitive to safety concerns to switch qualied drugs to
OTC. Creating a third class of drugs could be the answer consumers desire and
the FDA can accept.
The American Pharmaceutical Association has urged the creation
of a third class of drugs for some time. As alluded to above in the discussion
of H2-blockers and oral contraceptives, the third class would be a compromise
between prescription and OTC drugs. It would be a pharmacist-only class of
drugs.
The third class of drugs would combine the benets of OTC ther-
apy and patient counseling.23 According to the APhA, pharmacists have been
21OCs o-t-c?, The Lancet, vol. 342, September 4, 1993, 565.
22ibid 566.
23Sara Martin, Is a Third Class of Drugs in Pharmacy's Future?, American Pharmacy, vol.
N531, April 1991, 285.
15shown to reduce drug misuse, help patients choose the most appropriate med-
ication, and help prevent drug interactions. Surveys continue to show high
credibility ratings for pharmacists. Studies also show that pharmacists are the
most accessible health care resource.
One concrete example of how eective pharmacists can be comes
from a study completed in California in 1992. One thousand seven hundred and
thirteen consumers in ve stores in southern California were provided consulta-
tion during a 6-month period. Whether the counseling was eective or not was
measured by whether the customer purchased a dierent product than was in-
tended when he or she entered the store. 25.4% purchased a dierent drug than
intended when entering the store. 1.3% were referred to a physician. 13.4%
did not purchasing any OTC drugs at all.24 The results clearly shows that
consumers can benet from pharmacist counseling. Also noticeable is that this
counseling can save money because patients can be advised against purchasing
a drug they do not need.
Candidates for an OTC switch have already passed the rigorous
clinical trials in order to be approved as prescription drugs. The FDA's pri-
mary concern when failing to approve a switch most often centers around the
patient's inability to safely use the drug without a physician's supervision. The
hypersensitivity and paternalistic instinct would be reduced if the agency knew
a pharmacist was overseeing the drug's use. Further detailed insight into how
a third class of drugs could be benecial is provided by the three examples in
24Michael B. Nichol, et al., The Eects of Consultation on Over-the-Counter Medication
Purchasing Decisions, Medical Care, vol. 30, November 1992, 989.
16section IV (rogaine, H2-blockers, and oral contraceptives).
The committee which rejected Upjohn's switch application for ro-
gaine was concerned with patient misdiagnosis. A pharmacist could help the
patient decide whether his or her baldness is appropriate for the drug. Thus,
the patient has the best of both worlds. The patient can avoid the expense
and hassle of a doctor's appointment while also avoid taking rogaine in vain for
several months.
As mentioned above, the H2-blockers have not been approved pri-
marily because of adverse drug interaction concerns. A pharmacist could nd
out what drugs the patient is taking and decide if adverse drug interactions
are a possibility. In fact, because the pharmacist would have the patient's drug
record, the pharmacist might be in a better position to do this than a physician.
A third class of drugs would be ideal for oral contraceptives. The
pharmacist could counsel the patient on all the possible side eects and explain
the possible side eects if the patient cannot understand the label. Even more
importantly, the pharmacist would be more accessible than a physician. Thus, if
the patient had further questions or needed further monitoring, the pharmacist
could provide that assistance.
One last benet which must be mentioned from the creation of
a third class of drugs. A third class of drugs would decrease the amount of
direct marketing to physicians currently taking place by the pharmaceutical
industry. Of course, the drug industry would focus its eyes on pharmacists
instead. However, since the drug would eventually be moved to full OTC status
17as safety concerns are alleviated, direct marketing to pharmacists would be
short-lived.
b.More detailed labeling.
Coinciding with the creation of a third class of drugs should be more
detailed labelling and warnings of possible side eects. While studies show that
consumers frequently ignore warning labels and instructions, the presence of a
pharmacist can help solve that problem. Even if the pharmacist was unable to
explain the entire package insert of label, she could explain the more important
details. The patient could then retain the labelling and refer to it if there are
further questions. At the very least, the pharmacist could stress the importance
of reading the package labelling and keeping it for future reference.
Fortunately, persuading the FDA to require more detailed labelling
on drugs would not be dicult. Labelling has been a common tool for the FDA
to disseminate needed health information.
A brief article in Clinical Pharmacy provides an example. In Novem-
ber, 1993, the FDA announced that three categories of drugs would require new
warnings. Antacids were required to warn of adverse drug reactions. Laxatives
containing water-soluble gums were required to warn the consumer to take the
product with plenty of water. Last, sleep aids were required to warn consumers
not to take the drug if the patient suered from certain conditions.25 By re-
quiring such labelling the FDA reveals a belief that the consumer is somewhat
capable of understanding labelling. With a pharmacist's assistance, the FDA
25Three Categories of Nonprescription Drug Products to Carry New Warnings,
Clinical Pharmacy, vol 12, Nov. 1993, 800.
18can rest even easier.
VI.CONCLUSION
Switching more drugs over to OTC status via a third class of drugs
deserves consideration. While such a move would not cure all of this nation's
health care woes by any means, it would be a step in the right direction. People
should be empowered to control their own lives. They should not be held hostage
by a greedy prescription drug company, nor should they put blind faith in a self-
interested health care industry. To paraphrase Nancy Buc, Who's in charge of
our own body anyway - the doctor, the FDA, the drug company, or us?
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